Authors

Latest:

eContour: Evidence-Based Interactive Contouring Resources at the Point of Care

eContour is a novel, web-based, interactive contouring resource that aims to facilitate access to decision support through high-yield radiation treatment recommendations that are free and available at the point of care.

James E. Hoffman, MD

Latest:

Dr. Hoffman Discusses Challenges in Relapsed/Refractory Myeloma

James E. Hoffman, MD, assistant professor of clinical medicine at Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses remaining challenges in the field of relapsed/refractory myeloma.

James Gerson, MD

Latest:

Surviving the Marathon

A chance encounter while running an ultramarathon energized James Gerson, MD, to finish the race, and fueled his devotion and compassion afterward.

James Gulley, MD, PhD

Latest:

Dr. Gulley on Take Home Message With Olaparib Plus Durvalumab in mCRPC

James Gulley, MD, PhD, chief, Genitourinary Malignancies Branch, and director, Medical Oncology Service at the National Cancer Institute, discusses the take-home message with the combination of olaparib (Lynparza) plus durvalumab (Imfinzi) in metastatic castration-resistant prostate cancer.

James I. Geller, MD

Latest:

Dr. Geller on Renal Rhabdoid Tumors in Pediatric Patients

James I. Geller, MD, medical director, Kidney and Liver Tumors Program, Cincinnati Children’s Hospital Medical Center, discusses renal rhabdoid tumors in pediatric patients.

James J. Harding, MD

Latest:

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

Dr Harding discusses the significance of the FDA approval of zanidatamab for patients with HER2-positive metastatic biliary tract cancer.

James J. Hsieh, MD

Latest:

Dr. Hsieh on Patient Characterization From RECORD-3 Study in Metastatic RCC

James J. Hsieh, MD, medical oncologist, physician-scientist, Memorial Sloan Kettering Cancer Center, discusses overall survival results in the RECORD-3 study based on 3 distinct clear cell metastatic renal cell carcinoma molecular subgroups.

James J. Hsieh, MD, PhD

Latest:

Dr. Hsieh on Unmet Needs of Rare Kidney Cancer Variants

James J. Hsieh, MD, PhD, discusses unmet needs in non-clear cell renal cell carcinoma.

James J. Hsieh, MD, PhD, Washington University School of Medicine

James J. Lee, MD, PhD

Latest:

Dr. James Lee on Overcoming Mismatched Repair in Colorectal Cancer

James J. Lee, MD, PhD, Assistant Professor of Medicine, Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, discusses mismatched repair in colorectal cancer.

James K. McCloskey II, MD

Latest:

Evolving Treatment Landscape of Myelofibrosis

Closing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.

James Kearns, MD

Latest:

Dr. Kearns on AEs Associated With Surgery in Prostate Cancer

James Kearns, MD, assistant professor of medicine, Levine Cancer Institute, discusses adverse events associated with surgery in patients with high-risk prostate cancer.

James L. Godwin, MD

Latest:

Dr. Godwin on Immunotherapy Efforts in Prostate Cancer

James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses immunotherapy efforts in prostate cancer.

James L. Gulley, MD, PhD

Latest:

Dr Gulley on the Investigation of PRGN-2009 Plus Bintrafusp Alfa in HPV-Associated Cancers

James L. Gulley, MD, PhD, discusses a phase 1 trial of PRGN-2009 alone and in combination with bintrafusp alfa in patients with recurrent and/or metastatic HPV-associated cancers.

James L. M. Ferrara MD, DSc

Latest:

New Test Could Guide More Precise Treatment of GVHD

A new test reveals which patients with leukemia and other blood disorders are likely to respond to treatment for graft-versus-host disease that develops after a stem cell transplant.

James L. Mohler, MD

Latest:

Dr. Mohler on Recommendations for Genetic Testing in Prostate Cancer

James L. Mohler, MD, professor of oncology, associate director, and senior vice president of Translational Research, chief of Inter-Institutional Academics at Roswell Park Comprehensive Cancer Center, discusses recommendations for performing genetic testing in prostate cancer.

James L. Mulshine, MD

Latest:

Dr. Mulshine Discusses New Recommendations for Lung Cancer Screening

James L. Mulshine, MD, professor, Associate Provost for Research, Vice President, Rush University Medical Center discusses new USPSTF recommendations for lung cancer screening.

James Larkin, MD, PhD

Latest:

Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.

James Larner, MD

Latest:

Dr. Larner on Integrating Radiation Therapy With Immune Checkpoint Blockade in NSCLC

James Larner, MD, professor and chair of Radiation Oncology, University of Virginia Health System, discusses integrating radiation therapy with immune checkpoint blockade in patients with non–small cell lung cancer (NSCLC).

James M. Cleary MD, PhD

Latest:

BRAF-Mutated Colorectal Cancer: Early Frustrations and Future Optimism

This review highlights that preclinical data and discusses several ongoing clinical trials that are leveraging this information to explore new therapeutic strategies in targeting BRAF-mutated colorectal cancer.